Takeda takes a cautious step into neurological gene therapy, inking preclinical deal with StrideBio
Saddled with debt and keen to divest non-core business amid the ongoing integration of Shire, Takeda has nevertheless dished out a small sum to beef up its neuroscience research capacities, enlisting Durham, NC-based StrideBio to get started on some preclinical gene therapy candidates.
At $30 million upfront and just over $700 million in total deal value, this doesn’t qualify as a major deal at a time many top pharma companies are aggressively buying into the popping gene therapy space. But for Takeda — one of the biggest R&D spenders globally — it’s a way of signalling that it’s still very much active around the neurosciences deal table, seeking fresh assets to feed into its pipeline.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.